Document is current
Any future updates will be listed below
-
Authors
Shah, Jay
Devalaraju, Samanthika
Baerman, Elliot
Lee, Irene Jeong-Ah
Takigawa, Kei
Machado, Antonio Pizuorno
Catinis, Christine
Shatila, Malek
Varatharajalu, Krishnavathana
Shafi, Mehnaz
Lee, Hans C.
Strati, Paolo
Thomas, Anusha
Wang, Yinghong
- License Information
-
More Information
Article History
Received: 10 February 2024
Accepted: 20 March 2024
First Online: 5 July 2024
Declarations
:
: H.C.L: Consultancy: Abbvie, Bristol Myers Squibb, Genentech, Janssen, GlaxoSmithKline, Sanofi, Takeda, Allogene Therapeutics, Regeneron. Research funding: Bristol Myers Squibb, Janssen, GlaxoSmithKline, Takeda, Regeneron, Amgen. Y.W.: Consultancy: Sorriso, Janssen, Ilyapharma, Kanvas Bio, Biontech, Mallinckrodt Pharma.
: The ethics approval for this study was granted by the institutional review board at The University of Texas MD Anderson Cancer Center (2021-0100). Patient consent was waived for this study.
